xermelo- telotristat ethyl tablet
lexicon pharmaceuticals, inc. - telotristat ethyl (unii: 8g388563m7) (telotristat - unii:381v4fcv2z) - telotristat ethyl 250 mg - xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy. none. risk summary there are no human data with xermelo use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral telotristat ethyl to rats during organogenesis at doses up to 750 mg/kg/day (approximately 9 times the exposure at the rhd [recommended human dose]). treatment of pregnant rabbits with oral telotristat ethyl during organogenesis produced maternal toxicity and post-implantation loss at doses of 250 mg/kg/day or higher (approximately 15 times the exposure at the rhd), and reduced fetal weight at 500 mg/kg/day (approximately 33 times the exposure at the rhd). in a pre-/postnatal development study, an increased incidence of mortality in rat offspring was observed during postnatal days 0 to 4 at the maternal oral do
xermelo 250 mg
medison pharma ltd - telotristat ethyl as etiprate - film coated tablets - telotristat ethyl as etiprate 250 mg - xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (ssa) therapy in adults inadequately controlled by ssa therapy.
xermelo- telotristat ethyl tablet
tersera therapeutics llc - telotristat ethyl (unii: 8g388563m7) (telotristat - unii:381v4fcv2z) - xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy. xermelo is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. reactions have included angioedema, rash and pruritis. risk summary there are no human data with xermelo use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral telotristat ethyl to rats during organogenesis at doses up to 750 mg/kg/day (approximately 9 times the exposure at the rhd [recommended human dose]). treatment of pregnant rabbits with oral telotristat ethyl during organogenesis produced maternal toxicity and post-implantation loss at doses of 250 mg/kg/day or higher (approximately 15 times the exposure at the rhd), and reduced fetal weight at 500 mg/kg/day (approximately 33 times the exposure at the rhd). in a pr
xermelo- telotristat ethyl tablet
lexicon pharmaceuticals, inc. - telotristat ethyl (unii: 8g388563m7) (telotristat - unii:381v4fcv2z) - xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy. none. risk summary there are no human data with xermelo use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral telotristat ethyl to rats during organogenesis at doses up to 750 mg/kg/day (approximately 9 times the exposure at the rhd [recommended human dose]). treatment of pregnant rabbits with oral telotristat ethyl during organogenesis produced maternal toxicity and post-implantation loss at doses of 250 mg/kg/day or higher (approximately 15 times the exposure at the rhd), and reduced fetal weight at 500 mg/kg/day (approximately 33 times the exposure at the rhd). in a pre-/postnatal development study, an increased incidence of mortality in rat offspring was observed during postnatal days 0 to 4 at the maternal oral do
xermelo tablet
serb sas - telotristat ethyl (telotristat etiprate) - tablet - 250mg - telotristat ethyl (telotristat etiprate) 250mg - antidiarrhea agents
xermelo
serb sas - telotristat etiprate - carcinoid tumor; neuroendocrine tumors - other alimentary tract and metabolism products - xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (ssa) therapy in adults inadequately controlled by ssa therapy.
xermelo telotristat ethyl (as telotristat etiprate) 250 mg film-coated tablet blister pack
clinect pty ltd - telotristat etiprate, quantity: 327.9 mg (equivalent: telotristat ethyl, qty 250 mg) - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; lactose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy.
xermelo 250mg tablets
ipsen ltd - telotristat ethyl - tablet - 250mg
noristerat 200mg/1ml solution for injection ampoules
bayer plc - norethisterone enantate - solution for injection - 200mg/1ml
noristerat solution for injection
bayer pharma ag bayer pharma ag 13342 berlin germany - norethisterone enanthate - solution for injection - 1 ml noristerat contains 200 mg norethisterone - hormonal contraceptives: progestogens for